These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 20408841

  • 1. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations.
    Sugimoto Y, Muramatsu H, Makishima H, Prince C, Jankowska AM, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski JP.
    Br J Haematol; 2010 Jul; 150(1):83-7. PubMed ID: 20408841
    [Abstract] [Full Text] [Related]

  • 2. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B, Kosmider O, Cassinat B, Renneville A, Lachenaud J, Kaltenbach S, Bertrand Y, Baruchel A, Chomienne C, Fontenay M, Preudhomme C, Cavé H.
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [Abstract] [Full Text] [Related]

  • 3. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N, Yagasaki H, Xu Y, Matsuda K, Yoshimi A, Takahashi Y, Hama A, Nishio N, Muramatsu H, Watanabe N, Matsumoto K, Kato K, Ueyama J, Inada H, Goto H, Yabe M, Kudo K, Mimaya J, Kikuchi A, Manabe A, Koike K, Kojima S.
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [Abstract] [Full Text] [Related]

  • 4. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
    Gelsi-Boyer V, Trouplin V, Roquain J, Adélaïde J, Carbuccia N, Esterni B, Finetti P, Murati A, Arnoulet C, Zerazhi H, Fezoui H, Tadrist Z, Nezri M, Chaffanet M, Mozziconacci MJ, Vey N, Birnbaum D.
    Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
    [Abstract] [Full Text] [Related]

  • 5. Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia.
    Matsuda K, Sakashita K, Taira C, Tanaka-Yanagisawa M, Yanagisawa R, Shiohara M, Kanegane H, Hasegawa D, Kawasaki K, Endo M, Yajima S, Sasaki S, Kato K, Koike K, Kikuchi A, Ogawa A, Watanabe A, Sotomatsu M, Nonoyama S, Koike K.
    Br J Haematol; 2010 Feb; 148(4):593-9. PubMed ID: 19874312
    [Abstract] [Full Text] [Related]

  • 6. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS, Lee JW, Kang D, Yu H, Kim Y, Kang H, Lee JM, Ahn A, Cho B, Kim S, Chung NG, Kim Y, Kim M.
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [Abstract] [Full Text] [Related]

  • 7. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
    Flotho C, Steinemann D, Mullighan CG, Neale G, Mayer K, Kratz CP, Schlegelberger B, Downing JR, Niemeyer CM.
    Oncogene; 2007 Aug 23; 26(39):5816-21. PubMed ID: 17353900
    [Abstract] [Full Text] [Related]

  • 8. Mutations of the PTPN11 and RAS genes in rhabdomyosarcoma and pediatric hematological malignancies.
    Chen Y, Takita J, Hiwatari M, Igarashi T, Hanada R, Kikuchi A, Hongo T, Taki T, Ogasawara M, Shimada A, Hayashi Y.
    Genes Chromosomes Cancer; 2006 Jun 23; 45(6):583-91. PubMed ID: 16518851
    [Abstract] [Full Text] [Related]

  • 9. Juvenile myelomonocytic leukaemia and Noonan syndrome.
    Strullu M, Caye A, Lachenaud J, Cassinat B, Gazal S, Fenneteau O, Pouvreau N, Pereira S, Baumann C, Contet A, Sirvent N, Méchinaud F, Guellec I, Adjaoud D, Paillard C, Alberti C, Zenker M, Chomienne C, Bertrand Y, Baruchel A, Verloes A, Cavé H.
    J Med Genet; 2014 Oct 23; 51(10):689-97. PubMed ID: 25097206
    [Abstract] [Full Text] [Related]

  • 10. Hemophagocytosis associated with leukemia: a striking association with juvenile myelomonocytic leukemia.
    Unal S, Cetin M, Kutlay NY, Elmas SA, Gumruk F, Tukun A, Tuncer M, Gurgey A.
    Ann Hematol; 2010 Apr 23; 89(4):359-64. PubMed ID: 19798502
    [Abstract] [Full Text] [Related]

  • 11. Juvenile myelomonocytic leukemia with PTPN11 mutation in a 23-month-old girl.
    Jakovljević G, Kardum-Skelin I, Rogosić S, Nakić M.
    Coll Antropol; 2010 Mar 23; 34(1):251-4. PubMed ID: 20432758
    [Abstract] [Full Text] [Related]

  • 12. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
    Park HD, Lee SH, Sung KW, Koo HH, Jung NG, Cho B, Kim HK, Park IA, Lee KO, Ki CS, Kim SH, Yoo KH, Kim HJ.
    Ann Hematol; 2012 Apr 23; 91(4):511-7. PubMed ID: 21901340
    [Abstract] [Full Text] [Related]

  • 13. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
    Koike K, Matsuda K.
    Br J Haematol; 2008 May 23; 141(5):567-75. PubMed ID: 18422786
    [Abstract] [Full Text] [Related]

  • 14. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
    Tanaka M, Takahashi Y, Xu Y, Yoshida N, Yoshimi A, Villalobos IB, Hama A, Nishio N, Hidaka H, Wang Y, Yagasaki H, Kojima S.
    Leuk Res; 2008 Jul 23; 32(7):1036-42. PubMed ID: 18164384
    [Abstract] [Full Text] [Related]

  • 15. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
    Hamdy N, Bokhary H, Elsayed A, Hozayn W, Soliman S, Salem S, Alsheshtawi K, Abdalla A, Hafez H, Hammad M.
    Clin Lymphoma Myeloma Leuk; 2020 Jul 23; 20(7):e368-e374. PubMed ID: 32209330
    [Abstract] [Full Text] [Related]

  • 16. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM, Flotho C.
    Blood; 2019 Mar 07; 133(10):1060-1070. PubMed ID: 30670449
    [Abstract] [Full Text] [Related]

  • 17. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
    Lasho T, Patnaik MM.
    Best Pract Res Clin Haematol; 2020 Jun 07; 33(2):101171. PubMed ID: 32460983
    [Abstract] [Full Text] [Related]

  • 18. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia.
    Gratias EJ, Liu YL, Meleth S, Castleberry RP, Emanuel PD.
    Pediatr Blood Cancer; 2005 Feb 07; 44(2):142-6. PubMed ID: 15390271
    [Abstract] [Full Text] [Related]

  • 19. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia.
    Muramatsu H, Makishima H, Jankowska AM, Cazzolli H, O'Keefe C, Yoshida N, Xu Y, Nishio N, Hama A, Yagasaki H, Takahashi Y, Kato K, Manabe A, Kojima S, Maciejewski JP.
    Blood; 2010 Mar 11; 115(10):1969-75. PubMed ID: 20008299
    [Abstract] [Full Text] [Related]

  • 20. [Molecular biology of juvenile myelomonocytic leukemia (JMML)].
    Manabe A.
    Rinsho Ketsueki; 2010 Jul 11; 51(7):526-31. PubMed ID: 20693772
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.